Clinical Trials · NCT06397703
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- NYU Langone Health
- Enrollment
- 392
- Start date
- Apr 2024
- Locations
- 1 site, United States
- Primary endpoint
- Disease-Free Survival